Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/16/15
End: 10/19/24
Due: 10/19/25
Phase: N/A
Priority: Normal
Start: 05/17/18
End: 02/10/20
Due: 02/10/21
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer | NCT02531932 | Amy Tiersten | user2@example.com | None | 2015-12-16 | 2024-10-19 | 2025-10-19 | - | - | 2025-07-14 |
| Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | NCT03430518 | Amy Tiersten | user2@example.com | None | 2018-05-17 | 2020-02-10 | 2021-02-10 | - | - | 2025-07-14 |